[1]廖　健　杨文涛　李群生　周　磊　韦文华.Peyronie病的临床治疗进展[J].大众科技,2021,23(3):64-66.
　Progress in Clinical Treatment of Peyronies Disease[J].Popular Science & Technology,2021,23(3):64-66.
点击复制

Peyronie病的临床治疗进展()
分享到：

《大众科技》[ISSN:1008-1151/CN:45-1235/N]

卷:
23
期数:
2021年3
页码:
64-66
栏目:
医药与卫生
出版日期:
2021-03-20

文章信息/Info

Title:
Progress in Clinical Treatment of Peyronies Disease
作者:
廖　健1　杨文涛2　李群生2　周　磊2　韦文华1
（1.广西中医药大学研究生院，广西 南宁 530001； 2.广西中医药大学附属瑞康医院，广西 南宁 530011）
关键词:
Peyronie病; 病因; 阴茎白膜; 治疗
Keywords:
Peyronies disease etiology tunica albuginea of the penis treatment
文献标志码:
A
摘要:
Peyronie病（Peyronies disease，PD）目前病因尚不明确，许多专家认为是性交引起地阴茎白膜反复损伤导致其创伤修复障碍，在阴茎海绵体白膜发生病变，胶原沉积形成纤维斑块组织。Peyronie病不仅引起患者身体的畸形，还会对患者造成心理障碍。目前对Peyronie病的病理生理的过程并不完全明确，许多临床研究结果存在前后矛盾，文章就近年来的Peyronie病的临床治疗进展做一综述。
Abstract:
The etiology of Peyronies disease (PD) is still unclear currently. Many experts believe that it is sexual intercourse that causes the repeated damage of the tunica albuginea of the penis, which leads to the impairment of wound repair. The tunica albuginea of the corpus cavernosum of the penis develops lesions, and collagen deposition forms fibrous plaque tissue. Peyronies disease is not only a deformity of the patients body, but also cause psychological disorders to patients. At present, the pathophysiological process of Peyronies disease is not completely clear, and there are many inconsistencies in the clinical research results. This paper reviews the recent advances in the clinical treatment of Peyronies disease.

参考文献/References:

[1]　Schwarzer U, Sommer F, Klotz T, et al. The prevalence of Peyronies disease: results of a large survey[J]. British Journal of Urology International, 2001, 88(7): 727-730. [2]　Mulhall J P, Creech S D, Boorjian S A, et al. Subjective and objective analysis of the prevalence of Peyronies disease in a population of men presenting for prostate cancer screening[J]. The Journal of urology, 2004，171(6): 2350-2353. [3]　Arafa M, Eid H, El-Badry A, et al. The prevalence of Peyronies disease in diabetic patients with erectile dysfunction[J]. International journal of impotence research, 2007, 19(2): 213-217. [4]　Grasso M, Lania C, Blanco S, et al. The natural history of Peyronies disease[J]. Archivos Españoles de Urología, 2007, 60(3): 326-331. [5]　Carrieri M P, Serraino D, Palmiotto F, et al. A study on risk factors for Peyronies disease[J]. Journal of Clinical Epidemiology, 1998, 51(6): 511-515. [6]　Jarow J P, Lowe F C. Penile trauma: an etiologic factor in Peyronie disease and erectile dysfunction[J]. The Journal of Urology, 1997, 158(4): 1388-1390. [7]　Sporn M B, Roberts A B, Wakefield L M, et al. Some recent advances in the chemistry and biology of transforming growth factor-beta[J]. Journal of Cell Biology, 1987, 105(3): 1039-1045. [8]　El-Sakka A I, Hassoba H M, Chui R M, et al. An animal model of Peyronie-like condition associated with an increase of transforming growth factor beta mRNA and protein expression[J]. The Journal of Urology, 1997, 158(6): 2284-2290. [9] Ralph DJ, Brooks MD, Bottazzo GF, et al. The treatment of Peyronies disease with tamoxifen[J]. International Brazilian Journal of Urology, 1992, 70: 648-651. [10] James M J, Gibson R A, Cleland L G. Dietary polyunsaturated fatty acids and inflammatory mediator production[J]. The American Journal of Clinical Nutrition, 2000, 71(1): 343s-348s. [11] Safarinejad M R. Efficacy and safety of omega-3 for treatment of early-stage Peyronies disease: a prospective, randomized, double-blind placebo-controlled study[J]. The Journal of Sexual Medicine, 2009, 6(6): 1743-1754. [12] Schandene L, Vandenbussche P, Crusiaux A, et al. Di-fferential effects of pentoxifylline on the production oftumour necrosis factor-alpha (TNF-alpha) and inter-leukin-6 (IL-6) by monocytes and T cells[J]. Immunology, 1992, 76(1): 30-34. [13] Raetsch C, Jia J D, Boigk G, et al. Pentoxifylline downregulates profibrogenic cytokines and procollagen I expression in rat secondary biliary fibrosis[J]. Gut, 2002 50(2): 241-247. [14] Gelbard MK, James K, Riach P, et al. Collagenase versus placebo in the treatment of Peyronies disease: a double-blind study[J]. The Journal of Urology, 1993, 149(1): 56-58. [15] Duncan M R, Berman B, Nseyo U O. Regulation of the proliferation and biosynthetic activities of cultured human Peyronies disease fibroblasts by interferons-alpha, -beta and -gamma[J]. Scandinavian Journal of Urology and Nephrology, 1991, 25: 89-94. [16] Stewart C A, Yafi F A, Knoedler M, et al. Intralesional injection of interferon-alpha2b improves penile curvature in men with Peyronies disease independent of plaque location[J]. The Journal of Urology, 2015, 194: 1704-1707. [17] Abdel-Salam Y, Budair Z, Renner C, et al. Treatment of Peyronies disease by extracorporeal shockwave therapy: evaluation of our preliminary results[J]. Journal of Endourology, 1999, 13(8): 549-552. [18] Hamm R, McLarty E, Ashdown J, et al. Peyronies disease the Plymouth experience of extracorporeal shockwave treatment[J]. BJU International, 2001, 87(9): 849-852. [19] Wang C, Wang F, Yang K, et al. Shock wave therapy induces neovascularization at the tendon-bone junction: A study in rabbits[J]. Journal of Orthopaedic Research, 2003, 21: 984-989. [20] Lin G, Reed-Maldonado A, Wang B, et al. In situ activation of penile progenitor cells with low-intensity extracorporeal shockwave therapy[J]. The Journal of Sexual Medicine, 2017, 14: 493-501. [21] Hauck E, Hauptmann A, Bschleipfer T, et al. Questionable efficacy of extracorporeal shock wave therapy for Peyronies disease: results of a prospective approach[J]. The Journal of Urology, 2004, 171: 296-299. [22] Incrocci L, Wijnmaalen A, Slob A K, et al. Low-dose radiotherapy in 179 patients with Peyronie disease: treatment outcome and current sexual functioning[J]. International Journal of Radiation Oncology Biology Physics, 2000, 47(5): 1353-1356. [23] Incrocci L, Hop W C J, Seegenschmiedt H M. Radiotherapy for Peyronies disease: a European survey[J]. Acta Oncologica, 2008, 47(6): 1110-1112. [24] Levine L A, Newell M, Taylor F L. Penile traction therapy for treatment of Peyronies disease: a single-center pilot study[J]. Journal of Sexual Medicine, 2010, 5(6): 1468-1473. [25] Hatzimouratidis K, Eardley I, Giuliano F, et al. EAU Guidelines on Penile Curvature[J]. European Urology, 2012 62: 543-552. [26] Garcia-Gomez B, Ralph D, Levine L, et al. Grafts for Peyronies disease: a comprehensive review[J]. Andrology, 2018, 6: 117-126.

相似文献/References:

[1]李春秀 庞健丽.2 型糖尿病合并非酒精性脂肪肝的 中医临床研究进展[J].大众科技,2019,21(02):61.
　Clinical Research Progress of TCM Treatment for Type 2 Diabetes with Nonalcoholic Fatty Liver Disease[J].Popular Science & Technology,2019,21(3):61.
[2]蒙华莹 谢 胜 刘建来.基于“调理气机”探析脾虚肝郁型功能性消化不良的病因及诊治进展[J].大众科技,2021,23(12):88.
　To Explore the Etiology, Diagnosis and Treatment of Functional Dyspepsia Caused by Spleen Deficiency and Liver Stagnation Based on "Regulating Qi Mechanism"[J].Popular Science & Technology,2021,23(3):88.

备注/Memo

备注/Memo:
【收稿日期】2021-01-15 【作者简介】廖健，男，湖南郴州人，广西中医药大学研究生院在读硕士研究生，研究方向为中西结合男性病诊疗。 【通信作者】杨文涛（1972－），男，广西中医药大学附属瑞康医院主任医师，教授，硕士研究生导师，博士，研究方向为男性病诊疗。
更新日期/Last Update: 2021-06-02